CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

Stock Information for Tevogen Bio Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tevogen Bio Holdings Inc.

CNS Pharmaceuticals Announces CEO Transition
CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting
CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
IBN Announces Latest Episode of The BioMedWire Podcast Featuring John Climaco, CEO of CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update
CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.